World Heart Corp. (NSDQ:WHRT) won approval from the Food & Drug Administration to double the size of a clinical trial of its Levacor ventricular assist device.
The Salt Lake City-based company said the federal watchdog OK’d the addition of 10 additional sites to its bridge-to-transplant pivotal trial, taking the total number of eligible sites to 20.
In June, Mass. General Hospital and a pair of hospitals in Kentucky and Florida joined the study.
World Heart calls the Levacor device "the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trial," according to a press release.
